Cem Demirkiran, MD

Dr. Demirkiran is a dedicated medical professional and researcher who joined Yale University in 2021 to advance his passion for cancer research. As a core member of the Santin Lab, he has contributed significantly to both ex vivo and in vivo experiments, focusing on innovative approaches to cancer therapeutics.

In his role at the lab, Dr. Demirkiran utilized his expertise in mouse models, flow cytometry, ex vivo experiments, and statistical analysis to drive impactful research. His work, under the guidance of Dr. Santin and in collaboration with the lab team, has advanced the understanding of cancer biology, supported one pharmaceutical company in its pursuit of FDA approval for a cutting-edge cancer treatment, and contributed to ongoing research aimed at developing other therapeutic strategies for additional companies.

Dr. Demirkiran is also an active member of one of the oldest and largest scientific organizations in the world, exemplifying his dedication to collaboration and advancement within the global scientific community.

With a passion for translational medicine and innovation, Dr. Demirkiran continues to bridge the gap between laboratory discoveries and clinical applications. His contributions to the field reflect a steadfast commitment to improving patient outcomes and advancing cancer treatment strategies.